Objective: The article examines the objective, findings, and clinical context described in FDA approves giredestrant for breast cancer. Approach: Approval: The
The FDA approved giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after specified prior endocrine therapy.
The FDA authorized FoundationOne Liquid CDx as a companion diagnostic to identify patients with ESR1 mutations.
In the phase 3 evERA trial, median progression-free survival among patients with ESR1-mutated tumors was 10 months with giredestrant plus everolimus and 5.5 months with comparator endocrine therapy pl
Objective response rates in patients with ESR1-mutated tumors were 27% with giredestrant plus everolimus and 14% with comparator endocrine therapy plus everolimus; overall survival data were immature.
Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea; the prescribing information warns of bradycardia and embryo-fetal toxicity.
Objective: The article examines the objective, findings, and clinical context described in First IL-17A biologic approved for polymyalgia rheumatica. Approach:
The FDA approved secukinumab 150 mg as the first IL-17A inhibitor for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering.
In the 381-participant REPLENISH trial, sustained remission at week 52 occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab and 2,093 mg with placebo.
Median time to rescue treatment for a polymyalgia rheumatica flare was 282 days with secukinumab and 157 days with placebo.
The prescribing information warns of serious infections and inflammatory bowel disease and recommends tuberculosis evaluation and age-appropriate vaccinations before treatment.
Objective: The article examines the objective, findings, and clinical context described in FDA approves new pertuzumab biosimilar. Approach: Approval and availa
The FDA approved Biocon’s pertuzumab-qcay (Pebrilzo), a biosimilar to pertuzumab (Perjeta), for adults with HER2-positive breast cancer.
Approved uses include metastatic treatment with trastuzumab and docetaxel, neoadjuvant treatment with trastuzumab and chemotherapy, and adjuvant treatment for patients at high risk of recurrence.
Biocon reported that approval was supported by structural, functional, analytical, and comparative pharmacokinetic data showing high similarity to reference pertuzumab.
The earliest licensed US launch date for pertuzumab-qcay is the third quarter of 2028.
The accompanying safety information includes boxed warnings for left ventricular dysfunction and embryo-fetal toxicity, and lists diarrhea, alopecia, neutropenia, nausea, fatigue, and peripheral neuro
Objective: The article examines the objective, findings, and clinical context described in ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer. Key Findings: Among
Objective: The article examines the objective, findings, and clinical context described in ESMO26: Toni Choueiri, MD on LITESPARK-012. Approach: Study context:
Objective: The article examines the objective, findings, and clinical context described in ESMO26: Toni Choueiri, MD, on KEYNOTE-564. Approach: Follow-up: The f
Objective: The presentation covers the efficacy and safety of atirmociclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progressio
Objective: The article examines the objective, findings, and clinical context described in Is It Rejection – or Something Else?. Approach: Testing methods: Biop
Kidney biopsy and histology remain central to evaluating graft dysfunction, while molecular testing adds information about gene activity in sampled tissue.
Molecular results do not always establish the cause of injury and should be interpreted with histology, laboratory findings, and clinical history.
Creatinine changes can reflect rejection, infection, medication toxicity, reduced blood flow, obstruction, or recurrent disease, which may require different treatments.
Treating nonrejection injury as rejection by increasing immunosuppression could impair infection control, and immunosuppressive therapies carry other risks.
Blood- and urine-based biomarkers are under investigation for monitoring, but current evidence does not support using them as universal replacements for biopsy.
Objective: To track how AML-associated mutations and mutated blood-cell populations change before diagnosis, and assess whether these patterns distinguish peopl
In about two-thirds of participants who developed AML, the first cancer-associated mutation was estimated to have appeared before age 20.
Researchers used TETRIS-seq to track AML-associated mutations in annual blood samples from 47 women who later developed AML and 46 age-matched controls.
Mutated blood cell populations initially grew slowly, then expanded faster as they accumulated additional mutations, sometimes dominating blood production decades before diagnosis.
Age-related mutations occurred in both groups, but future AML cases showed more extensive expansion and competition among mutated cell populations.
The study did not establish a screening test; its small cohort and the lack of detectable warning in about one-fifth of AML cases require further validation.
DynaSpec combines metadynamics, density functional theory, and Raman spectroscopy to link glycan conformations with measured spectral features.
Glycans are difficult to sequence because they can branch, vary in linkage position and configuration, and occupy ensembles of conformations.
Raman spectra distinguished 13 N-glycan standards with greater than 85% average classification accuracy, including structures differing by one monosaccharide.
Simulations identified an open-to-curled conformational switch in all 13 glycans; G2 was estimated to be 90% open and 10% curled.
For positional isomers G1a and G1b, analysis of the 1,000-to-1,400 cm⁻¹ region achieved 71% discrimination using three times fewer features than full-spectrum analysis.
Objective: To identify plasma metabolite features associated with job stress among male manufacturing workers. Approach: Study design and participants: Cross-se
A cross-sectional study analyzed fasting plasma from 143 male manufacturing workers in Fuzhou, China, including 78 classified as experiencing job stress and 65 as not experiencing it.
Untargeted metabolomics identified 12 molecular features associated with job stress after adjustment for demographic and lifestyle factors; 11 were less abundant and 1 was more abundant in the stress
Accurate-mass searches tentatively linked the features mainly to lipids, and glycerophospholipid metabolism was the only pathway significant after correction for multiple comparisons.
A model combining 10 features distinguished the groups with 85.6% accuracy in internal validation, but it has not been tested in an independent cohort.
Metabolite identities remain tentative, and the study’s single-location, male-only, cross-sectional design and self-reported stress measure limit interpretation and cannot establish causation.
Objective: The article examines the objective, findings, and clinical context described in FDA approves first at-home agitation drug. Approach: Approval: The FD
Andres Sirulnik’s early family experience with leukemia helped shape his ambition to become a hematologist-oncologist.
After training in Argentina and England, Sirulnik learned to make monoclonal antibodies at Cambridge’s MRC Laboratory of Molecular Biology with César Milstein.
Sirulnik moved from patient care and academia to industry to pursue translational research and reach more patients through drug development.
Milstein taught Sirulnik to use precise language when describing data, a lesson that informs his science-driven approach to development.
Sirulnik says drug development should follow the science and address relevant problems for patients, clinicians, and the organization, while adapting to external hurdles.
Objective: To test whether transient delivery of modified mRNA encoding Myc and cyclin T1 could stimulate cardiomyocyte proliferation and improve heart function
Researchers developed modified messenger RNA encoding Myc and cyclin T1 to induce brief, localized expression of proteins that promote cardiomyocyte proliferation.
Widespread, sustained activation of Myc and cyclin T1 after myocardial infarction caused severe complications, with 7 of 8 genetically modified mice dying or requiring euthanasia.
In human embryonic stem cell-derived cardiomyocytes, the modRNA treatment activated cell cycle pathways and significantly increased cardiomyocyte proliferation.
In mice treated immediately after myocardial infarction, protein expression lasted less than 24 hours, while cardiac function improved for up to 12 weeks.
Treated mice had increased ventricular muscle area and cardiomyocyte division, but scar size was unchanged; no tumors were detected during 12 weeks of observation.
This 2-wave cohort study assessed whether baseline mental health need was associated with regular emotional-support generative AI use in 2025.
Among 6852 respondents without a usual source of care, weighted regular AI use rose from 4.6% with lower need to 20.7% with both high distress and current illness.
Compared with lower need, adjusted prevalence ratios for regular AI use were 1.67 with elevated need, 2.61 with high need, and 2.71 with both indicators.
The findings do not establish that AI use is therapeutic or safe, or that it can replace professional care.
Limitations included self-reported measures, a nonprobability internet-panel sample, possible selection and attrition bias, residual confounding, and no assessment of AI interaction content or safety.
Objective: The article examines the objective, findings, and clinical context described in HHS Provides Over $3 Million to Enhance Nutrition Programs for Older
HHS awarded USAging a 3-year cooperative agreement exceeding $3 million to support the National Resource Center on Nutrition and Aging.
The center will provide national leadership, training, technical assistance, data infrastructure, and resources to strengthen Older Americans Act Senior Nutrition Programs.
Senior Nutrition Programs deliver nearly 1 million meals daily through about 5,000 local providers, while approximately 10 million older adults experience hunger annually.
By 2029, the center aims to increase engagement in nutrition, social connection, and health-promotion activities by 15%.
The center will support local providers, share effective community-based approaches, and help connect older adults with nutrition and health-promotion services.